Northwestern Mutual Wealth Management Co. reduced its holdings of shares of West Pharmaceutical Services, Inc. (New York Stock Exchange: WST – Get a rating) by 11.6% during the 1st quarter, according to its last filing with the Securities and Exchange Commission (SEC). The institutional investor held 1,369 shares of the medical device supplier’s stock after selling 180 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in West Pharmaceutical Services were worth $562,000 at the end of last quarter.
Other institutional investors also changed their stake in the company. Allworth Financial LP increased its equity stake in West Pharmaceutical Services by 140.0% during the first quarter. Allworth Financial LP now owns 72 shares of the medical device supplier worth $30,000 after buying 42 more shares last quarter. Addison Advisors LLC increased its equity stake in West Pharmaceutical Services by 221.7% in Q1. Addison Advisors LLC now owns 74 shares of the medical device supplier worth $30,000 after buying 51 additional shares in the last quarter. Artemis Wealth Advisors LLC bought a new position in shares of West Pharmaceutical Services during Q1 worth approximately $35,000. American National Bank increased its stake in shares of West Pharmaceutical Services by 55.6% in the 1st quarter. American National Bank now owns 98 shares of the medical device supplier worth $40,000 after buying 35 more shares last quarter. Finally, Dividend Assets Capital LLC bought a new position in shares of West Pharmaceutical Services during Q4, valued at approximately $51,000. Institutional investors hold 93.25% of the company’s shares.
West Pharmaceutical Services shares down 0.7%
Shares of West Pharmaceutical Services Action opened at $319.52 on Friday. The company’s 50-day simple moving average is $313.16 and its 200-day simple moving average is $343.73. West Pharmaceutical Services, Inc. has a 52-week low of $275.89 and a 52-week high of $475.35. The company has a market capitalization of $23.66 billion, a PE ratio of 35.46, a P/E/G ratio of 1.30 and a beta of 1.15. The company has a debt ratio of 0.09, a quick ratio of 2.41 and a current ratio of 3.13.
Western Pharmaceutical Services (New York Stock Exchange: WST – Get a rating) last released its quarterly results on Thursday, July 28. The medical device supplier reported earnings per share of $2.47 for the quarter, beating the consensus estimate of $2.19 by $0.28. The company posted revenue of $771.30 million for the quarter, versus analyst estimates of $754.25 million. West Pharmaceutical Services achieved a return on equity of 29.08% and a net margin of 23.41%. The company’s quarterly revenue increased 6.6% year over year. In the same quarter of the previous year, the company achieved EPS of $2.46. On average, analysts predict that West Pharmaceutical Services, Inc. will post earnings per share of 9.13 for the current fiscal year.
A Wall Street analyst gives his opinion
Separately, StockNews.com downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a Thursday, April 28 research report.
Insiders place their bets
In other West Pharmaceutical Services news, an insider Silji Abraham sold 5,374 shares of the company in a transaction that took place on Monday, August 1. The stock was sold at an average price of $343.93, for a total transaction of $1,848,279.82. Following the transaction, the insider now owns 3,201 shares of the company, valued at approximately $1,100,919.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, accessible via the SEC website. Insiders hold 0.60% of the shares of the company.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc. designs, manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, Middle East, Africa and Asia-Pacific. It operates in two segments, Proprietary Products and Contract Manufactured Products.
Get daily news and reviews for West Pharmaceutical Services – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for West Pharmaceutical Services and related companies with MarketBeat.com’s free daily email newsletter.